Aprea Therapeutics, Inc. (APRE) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
9/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAPRE / S&P 5.11% / 15.20% |
LoseAPRE / S&P APRE unavailable / 15.00% |
LoseAPRE / S&P -54.78% / 50.40% |
| 2026-Q10/3 |
LoseAPRE / S&P -10.55% / -4.33% |
LoseAPRE / S&P APRE unavailable / 11.30% |
LoseAPRE / S&P -36.17% / 27.70% |
| 2025-Q40/3 |
LoseAPRE / S&P -42.17% / 2.65% |
LoseAPRE / S&P APRE unavailable / 9.00% |
LoseAPRE / S&P -17.80% / 13.40% |
| 2025-Q30/3 |
LoseAPRE / S&P -12.72% / 8.12% |
LoseAPRE / S&P APRE unavailable / 4.61% |
LoseAPRE / S&P -24.20% / 13.45% |
| 2025-Q20/3 |
LoseAPRE / S&P -17.16% / 10.94% |
LoseAPRE / S&P APRE unavailable / 4.83% |
LoseAPRE / S&P -24.09% / 10.63% |
| 2025-Q10/3 |
LoseAPRE / S&P -37.99% / -4.27% |
LoseAPRE / S&P APRE unavailable / 4.98% |
LoseAPRE / S&P -29.22% / 10.57% |
| 2024-Q41/3 |
WinAPRE / S&P 19.64% / 2.41% |
LoseAPRE / S&P APRE unavailable / 5.25% |
LoseAPRE / S&P -40.85% / 6.15% |
| 2024-Q30/3 |
LoseAPRE / S&P -32.43% / 5.89% |
LoseAPRE / S&P APRE unavailable / 5.89% |
LoseAPRE / S&P -122.90% / 6.11% |
| 2024-Q20/3 |
LoseAPRE / S&P -39.16% / 4.28% |
LoseAPRE / S&P APRE unavailable / 5.38% |
LoseAPRE / S&P -128.03% / 5.12% |
| 2024-Q11/3 |
WinAPRE / S&P 42.34% / 10.56% |
LoseAPRE / S&P APRE unavailable / 5.71% |
LoseAPRE / S&P -95.58% / 5.59% |
| 2023-Q41/3 |
WinAPRE / S&P 12.79% / 11.69% |
LoseAPRE / S&P APRE unavailable / 6.81% |
LoseAPRE / S&P -95.07% / 7.78% |
| 2023-Q31/3 |
WinAPRE / S&P 32.29% / -3.27% |
LoseAPRE / S&P APRE unavailable / 7.52% |
LoseAPRE / S&P -109.45% / -5.03% |
| 2023-Q20/3 |
LoseAPRE / S&P -29.05% / 8.74% |
LoseAPRE / S&P APRE unavailable / 9.50% |
LoseAPRE / S&P -108.45% / -8.57% |
| 2023-Q11/3 |
LoseAPRE / S&P -32.93% / 7.50% |
LoseAPRE / S&P APRE unavailable / 10.77% |
WinAPRE / S&P 80.08% / -15.69% |
| 2022-Q41/3 |
LoseAPRE / S&P -49.08% / 7.56% |
LoseAPRE / S&P APRE unavailable / 11.88% |
WinAPRE / S&P 132.08% / -17.99% |
| 2022-Q31/3 |
LoseAPRE / S&P -13.33% / -4.88% |
LoseAPRE / S&P APRE unavailable / 13.47% |
WinAPRE / S&P 158.53% / -1.41% |
| 2022-Q21/3 |
LoseAPRE / S&P -59.68% / -16.10% |
LoseAPRE / S&P APRE unavailable / 13.71% |
WinAPRE / S&P 154.14% / 11.04% |
| 2022-Q10/3 |
LoseAPRE / S&P -35.19% / -4.60% |
LoseAPRE / S&P APRE unavailable / 15.97% |
LoseAPRE / S&P APRE unavailable / 42.23% |
| 2021-Q40/3 |
LoseAPRE / S&P -43.84% / 11.03% |
LoseAPRE / S&P APRE unavailable / 15.00% |
LoseAPRE / S&P APRE unavailable / 96.40% |
| 2021-Q31/3 |
WinAPRE / S&P 4.71% / 0.58% |
LoseAPRE / S&P APRE unavailable / 10.77% |
LoseAPRE / S&P APRE unavailable / 69.42% |
| 2021-Q20/3 |
LoseAPRE / S&P -4.31% / 8.55% |
LoseAPRE / S&P APRE unavailable / 6.58% |
LoseAPRE / S&P APRE unavailable / 51.81% |
| 2021-Q10/3 |
LoseAPRE / S&P 3.66% / 6.17% |
LoseAPRE / S&P APRE unavailable / -1.06% |
LoseAPRE / S&P APRE unavailable / 7.39% |
| 2020-Q40/3 |
LoseAPRE / S&P -79.55% / 12.15% |
LoseAPRE / S&P APRE unavailable / -3.72% |
LoseAPRE / S&P APRE unavailable / -33.42% |
| 2020-Q30/3 |
LoseAPRE / S&P -37.96% / 8.93% |
LoseAPRE / S&P APRE unavailable / -2.04% |
LoseAPRE / S&P APRE unavailable / -27.10% |
| 2020-Q20/3 |
LoseAPRE / S&P 11.57% / 20.54% |
LoseAPRE / S&P APRE unavailable / -0.46% |
LoseAPRE / S&P APRE unavailable / -27.11% |
| 2020-Q10/3 |
LoseAPRE / S&P -24.25% / -19.60% |
LoseAPRE / S&P APRE unavailable / 3.47% |
LoseAPRE / S&P APRE unavailable / -14.75% |
| 2019-Q40/3 |
LoseAPRE / S&P APRE unavailable / 9.07% |
LoseAPRE / S&P APRE unavailable / 5.36% |
LoseAPRE / S&P APRE unavailable / 2.99% |
| 2019-Q30/3 |
LoseAPRE / S&P APRE unavailable / 1.70% |
LoseAPRE / S&P APRE unavailable / 5.02% |
LoseAPRE / S&P APRE unavailable / 0.21% |
| 2019-Q20/3 |
LoseAPRE / S&P APRE unavailable / 4.30% |
LoseAPRE / S&P APRE unavailable / 6.64% |
LoseAPRE / S&P APRE unavailable / 8.65% |
| 2019-Q10/3 |
LoseAPRE / S&P APRE unavailable / 13.65% |
LoseAPRE / S&P APRE unavailable / 8.12% |
LoseAPRE / S&P APRE unavailable / 14.29% |
| 2018-Q40/3 |
LoseAPRE / S&P APRE unavailable / -13.52% |
LoseAPRE / S&P APRE unavailable / 9.05% |
LoseAPRE / S&P APRE unavailable / 18.23% |
| 2018-Q30/3 |
LoseAPRE / S&P APRE unavailable / 7.71% |
LoseAPRE / S&P APRE unavailable / 10.21% |
LoseAPRE / S&P APRE unavailable / 19.06% |
| 2018-Q20/3 |
LoseAPRE / S&P APRE unavailable / 3.43% |
LoseAPRE / S&P APRE unavailable / 9.03% |
LoseAPRE / S&P APRE unavailable / 14.46% |
| 2018-Q10/3 |
LoseAPRE / S&P APRE unavailable / -0.76% |
LoseAPRE / S&P APRE unavailable / 7.68% |
LoseAPRE / S&P APRE unavailable / 12.46% |
| 2017-Q40/3 |
LoseAPRE / S&P APRE unavailable / 6.64% |
LoseAPRE / S&P APRE unavailable / 7.03% |
LoseAPRE / S&P APRE unavailable / 13.82% |
| 2017-Q30/3 |
LoseAPRE / S&P APRE unavailable / 4.48% |
LoseAPRE / S&P APRE unavailable / 5.68% |
LoseAPRE / S&P APRE unavailable / 17.57% |
| 2017-Q20/3 |
LoseAPRE / S&P APRE unavailable / 3.09% |
LoseAPRE / S&P APRE unavailable / 4.83% |
LoseAPRE / S&P APRE unavailable / 17.74% |
| 2017-Q10/3 |
LoseAPRE / S&P APRE unavailable / 6.07% |
LoseAPRE / S&P APRE unavailable / 3.67% |
LoseAPRE / S&P APRE unavailable / 13.32% |
| 2016-Q40/3 |
LoseAPRE / S&P APRE unavailable / 3.82% |
LoseAPRE / S&P APRE unavailable / 2.09% |
LoseAPRE / S&P APRE unavailable / 7.05% |
| 2016-Q30/3 |
LoseAPRE / S&P APRE unavailable / 3.85% |
LoseAPRE / S&P APRE unavailable / 0.20% |
LoseAPRE / S&P APRE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | APRE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -45.05% | 20.78% |
| Annualized return | -45.05% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | APRE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.09% | 83.14% |
| Annualized return | -60.94% | 12.86% |
10Y · 2019-10-03 to 2026-08-27
| Metric | APRE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.79% | 319.30% |
| Annualized return | -46.03% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |